Following Brexit, Britain must pay to relocate the European Medicines Agency from London to a city within the EU and 19 European countries are placing their bids to be the next host. Indeed the EMA is favoured as being the most valuable of the Brexit spoils; its nature as one of the most prestigious European agencies bears both economic and political advantage for London's successor. Not only will it prove incredibly valuable for the victor of the fierce bidding war, its loss will be felt the British pharma industry.
Attachment
PDF
144.4 kB
PMLive_2017_10_16_a.pdf
